Evidence map›Paper›PMID 41179943›Full record

ArticleCancer pathogenesis and therapy2025

Radiotherapy combined with first-line anti-programmed cell death protein 1 (PD-1) immunotherapy and chemotherapy for patients with advanced non-small cell lung cancer: A bicentric retrospective study.

Yu Huang, Peng Ding, Ruiguang Zhang, Yongchang Zhang, Fan Tong, Shishi Cheng, Ling Peng, Xiaohua Jie, Jian Wang, Pian Liu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer pathogenesis and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yu HuangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Peng DingCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Ruiguang ZhangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Yongchang ZhangDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China.
Fan TongCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Shishi ChengCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Ling PengCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Xiaohua JieCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Jian WangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Pian LiuCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Sheng ZhangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Gang WuCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Nong YangDepartment of Oncology, The Second People's Hospital of Hunan, Changsha, Hunan 410007, China.
Xiaorong DongCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Several studies have demonstrated the synergistic effects of immunotherapy and radiotherapy for both local and abscopal tumor control. However, data regarding the use of first-line immunochemotherapy (ICT) combined with radiotherapy for advanced non-small cell lung cancer (NSCLC) remain limited. This study investigated the efficacy and safety of first-line immunochemotherapy combined with radiotherapy (ICRT) and those of ICT alone. Methods: Patients with advanced NSCLC who received first-line anti-programmed cell death protein 1 (PD-1) immunotherapy plus chemotherapy at Wuhan Union Hospital and Hunan Cancer Hospital between October 2017 and July 2021 were retrospectively analyzed. The objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety associated with treatment were assessed. Survival outcomes were analyzed using the Kaplan-Meier method. Results: A total of 194 patients were included: 92 were treated with ICRT and 102 were treated with ICT. The ORRs of the ICRT and ICT groups were 57.6% and 47.1%, respectively. Patients in the ICRT group had significantly longer PFS (median: 14.9 Conclusions: Radiotherapy is safe and manageable when added to first-line anti-PD-1 immunotherapy and chemotherapy for patients with advanced NSCLC.

Indexed as

ChemotherapyImmunotherapyNon-small cell lung cancerProgrammed cell death protein 1Radiotherapy

Identifiers

PMID41179943
PMCPMC12573630

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.